Methods for the rapid manufacture of conjugate vaccines that elicit robust immune responses
By expressing antigens in cell lines and conjugating them with toll-like receptor agonists, the method addresses the limitations of mRNA vaccines and traditional production methods, enabling rapid, cost-effective, and stable vaccines that provide broad protection against emerging variants.
WO2026080514A1 Publication Date: 2026-04-16INVENTPRISE INC
2 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/049896
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-07
- Filing Date
- 2025-10-07
- Publication Date
- 2026-04-16
AI Technical Summary
Technical Problem
Current mRNA vaccines require careful handling and cold chain storage, and their broad protection wanes rapidly, necessitating frequent boosters, while traditional vaccine production methods are costly and slow, especially in Low- and Middle-Income Countries (LMICs).
Method used
Express antigens in established cell lines, collect them, and conjugate with toll-like receptor agonists to create stable, cost-effective immunogenic compositions that can be stored at 2° - 8 °C, allowing rapid development of vaccines against emerging variants.
Benefits of technology
The method enables rapid, affordable production of broadly protective vaccines with long-term immunity, reducing the need for frequent boosters and cold chain storage, and effectively neutralizes variants of concern.
✦ Generated by Eureka AI based on patent content.
Abstract
The disclosures of the invention arc directed to the manufacture of effective, affordable vaccines that arc globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA CO VID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.l, BA.2, and BA.4 / BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.
Need to check novelty before this filing date? Find Prior Art